Search results

702 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
NICE Pathways Remove NICE Pathways filter
In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Public health guidelines Remove Public health guidelines filter

Weight Management

In development [GID-NG10182] Expected publication date: 22 June 2023

Type

NICE guideline

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 01 September 2021

Type

NICE guideline

Status

In development
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

In development
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

In development [GID-TA10545] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 14 April 2021

Type

Technology appraisal guidance

Status

In development
Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

In development [GID-TA10561] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

In development [GID-TA10653] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

In development [GID-TA10635] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 06 July 2022

Type

NICE guideline

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asthma: diagnosis, monitoring and chronic asthma management

In development [GID-NG10186] Expected publication date: TBC

Type

NICE guideline

Status

In development
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]

In development [GID-TA10538] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

In development [GID-TA10711] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Stroke rehabilitation in adults

In development [GID-NG10175] Expected publication date: 14 December 2022

Type

NICE guideline

Status

In development
Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 20 July 2021

Type

NICE guideline

Status

In development
Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]

In development [GID-TA10701] Expected publication date: 20 July 2022

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]

In development [GID-TA10669] Expected publication date: 04 May 2022

Type

Technology appraisal guidance

Status

In development
Inducing labour (update)

In development [GID-NG10082] Expected publication date: 14 October 2021

Type

NICE guideline

Status

In development
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 19 January 2022

Type

NICE guideline

Status

In development
Rehabilitation after traumatic injury

In development [GID-NG10105] Expected publication date: 23 November 2021

Type

NICE guideline

Status

In development
Depression in adults: treatment and management (update)

In development [GID-CGWAVE0725] Expected publication date: 12 May 2022

Type

NICE guideline

Status

In development
Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 08 September 2021

Type

NICE guideline

Status

In development